Paratek Pharmaceuticals to Present at the SVB Leerink 9th Annual Global Healthcare Conference
February 26, 2020 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Announces Full Year 2019 Total Revenues of $16.5 Million including NUZYRA® (omadacycline) Net Sales of $11.5 Million
February 25, 2020 16:01 ET
|
Paratek Pharmaceuticals
-- Paratek Expects Full Year 2020 Total Revenues to be Between $75 and $80 Million including NUZYRA Net Sales of Approximately $66 Million -- Paratek Now Anticipates its Cash Runway Will Extend...
Paratek Announces License Grant to Almirall for SEYSARA® (sarecycline) for Greater China Region
February 24, 2020 07:00 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
February 13, 2020 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Awarded BARDA Project BioShield Contract for NUZYRA®
December 18, 2019 17:12 ET
|
Paratek Pharmaceuticals
- Total award valued at up to $285 million - Paratek to host a conference call today, December 18, 2019 at 5:30 p.m. EST BOSTON, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc....
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 02, 2019 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals Generates Net Revenues of $3.9 Million in the Third Quarter of 2019
November 12, 2019 16:05 ET
|
Paratek Pharmaceuticals
-- Third Quarter 2019 NUZYRA® (omadacycline) Net Sales increased 82% versus the Prior Quarter to $3.1 Million -- -- Oral-only CABP Pharmacokinetics Study Initiated-- BOSTON, Nov. 12, 2019 (GLOBE...
Paratek Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019
November 04, 2019 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 01, 2019 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Announces Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract Infections
October 31, 2019 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...